最近，著名市场研究公司Allied发表报告称，未来RNA药物将呈现高速增长趋势，到2020年，这类药物销售额将有望突破12亿美元，平均年增长率将保持在28.4%左右。这一报告一经出炉，立刻引起了业界、投资者和科学家们的关 ...

安徽新一轮药品招标经济技术标入围品种公布，通化东宝（600867.SH）40/60混合重组人胰岛素注射液首次进入地方招标，独家品规中标放量可期。　　重组人胰岛素用于治疗糖尿病。目前，通化东宝的混合重组人胰岛素产品分 ...

安徽新一轮药品招标经济技术标入围品种公布，乐普医疗（300003.SZ）主打产品“帅信”（通用名“氯吡格雷”）惨遭淘汰，这也是本轮基药招标以来，“帅信”首次在经济技术标中直接出局。　　今年6月，安徽省规定，“未 ...

Sep. 15, 2014Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With OsteoporosisData Presented at t ...

Sep. 15, 2014New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral DensityRomosozumab Currently in Phase 3 Clinical Development, P ...

Sep. 14, 2014Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart FailureAnalysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for ...

Investor UpdateBasel, 15 September 2014Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)?No approved treatment exists for this advanced form of a ...

适应症：骨质疏松来源：默克官网Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis Merck now expects to sub ...

美国FDA最近批准了由阿斯利康公司和Nektar生物医药公司联合开发的新型鸦片类疗法naloxegol进入美国市场。这一药物是一种口服鸦片类受体抑制剂，能够在有效治疗便秘的同时，最大程度降低了传统鸦片类药物可能引起的肠 ...

优时比制药和安进于周二联合宣布，公司单抗药物Romosozumab在临床II期研究中表现良好。该药物适应对象为低骨密度的绝经期后妇女。Romosozumab是一种实验性完全人源化单抗药物，通过抑制蛋白质硬化素从而促进骨形成和 ...

转自：美中药源 据路透社9月16日报道，英国医疗和保健产品管理局（Medicines and Healthcare Products Regulatory Agency，MHRA）为Northwest Biotherapeutics（西北生物制药）治疗脑癌的疫苗DCVax-L颁发了“潜力创 ...

适应症：胰腺癌Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer-- Data to be Presented at European Society for Medical Oncology Congress in Madrid -- FO ...

Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes Omarigliptin significantly reduced HbA1c levels compared to ...

武田制药宣布，公司旗下糖尿病药物trelagliptin succinate (SYR-472)临床III期效果良好来源：武田官网的PDF文件，见附件

来源：生物谷法国生物医药巨头赛诺菲公司最近宣布将和旧金山生物技术公司MyKardia合作进行治疗心肌疾病相关新药的早期研发工作。据赛诺菲公司透露，此次协议至少涉及2亿美元，其中包括了研发过程中的里程碑资金，赛 ...